"Persisters": Survival at the cellular level

PLoS Pathogens

Volumn 7, Issue 7, 2011, Pages

  Dawson, Clinton C ^a   Intapa, Chaidan ^a   Jabra Rizk, Mary Ann ^a,b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL CELL; CANCER CELL; CANDIDA ALBICANS; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; DRUG TOLERANCE; ESCHERICHIA COLI; HUMAN; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ANIMAL; ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; BACTERIAL INFECTION; DRUG RESISTANCE; MYCOSIS; NEOPLASM; REVIEW;

ANIMALS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MYCOSES; NEOPLASMS;

EID: 79960964039     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002121     Document Type: Article

References (25)

1. Bigger J, (1944) Treatment of staphylococcal infections with penicillin. Lancet 244: 497-500.
2. Lewis K, (2007) Persister cells, dormancy and infectious disease. Nat Rev Micro 5: 48-56.
3. Lewis K, (2010) Persister cells. Ann Rev Microbiol 64: 357-372.
4. Al-Dhaheri RS, Douglas J, (2008) Absence of amphotericin B-tolerant persister cells in biofilms of some Candida species. Antimicrob Agents Chemother 52: 1884-1887.
5. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K, (2004) Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230: 13-18.
6. LaFleur MD, Kumamoto CA, Lewis K, (2006) Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50: 3839-3846.
7. Lewis K, (2008) Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322: 107-31.
8. Roberts ME, Stewart PS, (2005) Modeling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiol 151: 75-80.
9. Kaern M, (2005) Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet 6: 451-464.
10. Jayaraman A, Wood TK, (2008) Bacterial quorum sensing: signals, circuits, and implications for biofilms and disease. Ann Rev Biomed Eng 10: 145-167.
11. Vazquez-Laslop N, Lee H, Neyfakh AA, (2006) Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J Bacteriol 188: 3494-3497.
12. Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, et al. (2009) Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB. Science 323: 396-401.
13. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, et al. (2004) SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305: 1629-1631.
14. Dörr T, Vulić M, Lewis K, (2010) Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol 8: e1000317 doi:10.1371/journal.pbio.1000317.
15. Lewis K, (2001) Riddle of biofilm resistance. Antimicrob Agents Chemother 45: 999-1007.
16. Kumamoto CA, (2002) Candida biofilms. Curr Opin Microbiol 5: 608-611.
17. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K, (2004) Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 186: 872-880.
18. Jabra-Rizk MA, Falkler WA Jr, Meiller TF, (2004) Fungal biofilms and drug resistance. Emerg Infect Dis 10: 14-19.
19. Redmond KM, Wilson TR, Johnston PG, Longley DB, (2008) Resistance mechanisms to cancer chemotherapy. Front Biosci 13: 5138-5154.
20. Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, et al. (2004) Effect of re-treatment with gefitinib after acquisition of resistance. Ann Oncol 15: 173-174.
21. Yano S, Nakataki E, Ohtsuka S, Inayama M, Tomimoto H, et al. (2005) Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 15: 107-111.
22. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A Chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
23. Glasspool RM, Teodoridis J, Brown R, (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092.
24. Frank N, Schatton T, Frank MH, (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 20: 41-50.
25. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S, (2004) Bacterial persistence as a phenotypic switch. Science 305: 1622-1625.